Back pain: Ccn2a protein reversed Intervertebral disc (IVD) degeneration in animal model

In a recent in-vivo study on Zebrafish, researchers successfully induced disc regeneration in a degenerated disc by activating an endogenous Ccn2a-FGFR1-SHH signalling cascade. This suggests that Ccn2a protein could be exploited in promotion of IVD regeneration for treatment of backpain.  

Back pain is a common health problem. It is one of the most common reasons for people to seek appointment with doctors. The condition is mainly due to degeneration of intervertebral disc (IVD) which occurs naturally due to wear and tear or ageing. Analgesics and anti-inflammatories along with physiotherapy are currently used to treat the symptoms. In severe cases, disc replacement or disc fusion surgery may be resorted. As such, there is no cure. No known medical treatment or procedure is helpful in restoring disc homeostasis. The solution to the problem lies in finding a way to supress the disc degeneration and/or to induce disc regeneration.  

In an in-vivo study on Zebrafish, reported on 6th January 2023, the researchers discovered that Cellular communication network factor 2a (Ccn2a), a protein secreted by the cells of the intervertebral disc induces disc regeneration in old degenerated discs by promoting cell proliferation and cell survival by modulation of the FGFR1-SHH (Fibroblast growth factor receptor-Sonic Hedgehog) pathway.  

Apparently, this is for the first time that disc regeneration in a degenerated disc has been induced in vivo by activating an endogenous signalling cascade.  

This development may be a steppingstone towards designing a novel strategy to suppress disc degeneration or induce disc regeneration in degenerated human discs.  

*** 

References:  

Rayrikar A.Y., et al 2023. Ccn2a-FGFR1-SHH signaling is necessary for intervertebral disc homeostasis and regeneration in adult zebrafish. Development. Volume 150, Issue 1. Published 06 January 2023. DOI: https://doi.org/10.1242/dev.201036 

*** 

Latest

Brain-Computer Interfaces (BCI): Towards Humans’ Merger with AI 

The ongoing clinical trials of Brain-Computer Interfaces (BCIs) such...

Tumour Treating Fields (TTFields) approved for Pancreatic cancer

Cancer cells have electrically charged parts hence are influenced...

Scientific European invites Co-founder

Scientific European (SCIEU) invites you to join as a Co-Founder and investor, with both...

Future Circular Collider (FCC): CERN Council reviews Feasibility Study

The quest for the answers to the open questions (such as, which...

Chernobyl Fungi as Shield Against Cosmic Rays for Deep-Space Missions 

In 1986, the 4th unit of Chernobyl Nuclear Power Plant in Ukraine...

Myopia Control in Children: Essilor Stellest Eyeglass Lenses Authorised  

Myopia (or near-sightedness) in children is a highly prevalent...

Newsletter

Don't miss

Two Novel Henipaviruses Detected in Fruit bats in China 

The henipaviruses, Hendra virus (HeV) and Nipah virus (NiV) are known to cause...

New Understanding of Schizophrenia

A recent breakthrough study unearths anew mechanism of schizophrenia....

Enhancing Agricultural Productivity Through Establishing Plant Fungal Symbiosis

Study describes a new mechanism which mediates the symbiont...

Would Synthetic Embryos Usher in the Era of Artificial Organs?   

Scientists have replicated the natural process of mammalian embryonic...

The Possible Cure of Type 2 Diabetes?

The Lancet study shows that Type 2 diabetes can...

Climate Change: Reducing Carbon Emission from Aeroplanes

Carbon emission from commercial aircrafts could be reduced by about...
SCIEU Team
SCIEU Teamhttps://www.scientificeuropean.co.uk
Scientific European® | SCIEU.com | Significant advances in science. Impact on humankind. Inspiring minds.

Brain-Computer Interfaces (BCI): Towards Humans’ Merger with AI 

The ongoing clinical trials of Brain-Computer Interfaces (BCIs) such as Neuralink’s “Telepathy” implant involve establishing communication links between the brains of participants who have unmet medical needs due...

Tumour Treating Fields (TTFields) approved for Pancreatic cancer

Cancer cells have electrically charged parts hence are influenced by electric fields. Application of alternating electric fields (TTFields) to solid tumours selectively target and...

Scientific European invites Co-founder

Scientific European (SCIEU) invites you to join as a Co-Founder and investor, with both strategic investment and active contribution in shaping its future direction.  Scientific European is an England-based media outlet providing multilingual...